The company has developed a self-financed internal research and development program (R&D), aiming at new and/or improved laboratory techniques and reagents. Our intense efforts in the above fields have resulted in several publications in established international journals and to our continuous presence in international and Greek conferences, training seminars and postgraduate study courses.
In particular, the continuous research and development (R&D), has led to significant and pioneering applications, such as the expanded prenatal diagnosis panel (EPP), prenatal molecular karyotype, the development of a new method for the analysis of genomic imbalances in leukemias, carrier detection for the F508del and 35delG mutations in dry blood samples, preimplantation genetic diagnosis for rare genetic diseases, preimplantation genetic diagnosis coupled to HLA-matching which led to internationally pioneering applications, etc.
The era of Genomic Medicine and Next GenerationSequencing (NGS) is here and InterGenetics, following international developments, pioneered once again in this field, offering since 2011 on a clinical basis the analysis of all ~22,000 human genes (Whole Exome Sequencing – WES), being among the first clinical diagnostic laboratories worldwide with this capability.
Besides the massive analysis of all human genes, NGS technology also enables simultaneous analysis of hundreds of genes (NGS gene panels) related to different categories of diseases with a genetic etiology. In this context, InterGenetics developed several special NGS multi-gene panels, related to genetic diseases whose expression is associated with a large (> 10) number of genes, such as hearing loss, retinopathies, cancers, etc..
Finally, realizing the increasing demand for information from physicians, patients and the general public, we have systematically and carefully produced standardized brochures and information material relating to many aspects of medical genetics and which are offered before and after testing is completed.